LNP-nCoVsaRNA Vaccine Uses, Dosage, Side Effects and more
LNP-nCoVsaRNA is a purified, synthetic mRNA vaccine candidate encoding the S glycoprotein of SARS-CoV-2, which is used primarily by the virus to attach to and invade human cells. The vaccine was developed in and tested by the Medical Research Council Clinical Trials Unit at UCL in the UK, and jointly funded by UK Research and Innovation. As of July 2020, a clinical trial (COVAC1) is underway (ISRCTN17072692) to test the safety and immunogenicity of the vaccine.
| Trade Name | LNP-nCoVsaRNA Vaccine |
| Generic | LNP-nCoVsaRNA Vaccine |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
